



## **GENERIC HEALTH PTY LTD SECURES TOP 5 INDIAN PHARMACEUTICAL COMPANY AS SIGNIFICANT SHAREHOLDER**

**25 August 2008.** Biotech Capital Limited (ASX: BTC) is pleased to announce that it's investee company Generic Health Pty Ltd ("Generic Health") has secured a highly strategic partnership with Lupin Ltd – one of India's five largest pharmaceutical companies. Lupin generated revenues of US\$694m and profits of US\$102m for the 12 months to March 2008.

This partnership includes Lupin becoming a significant shareholder in Generic Health via a cash investment and obtaining Board representation.

This transaction positions Generic Health very strongly to continue the consolidation in the Australian generics sector and follows the acquisition of Bellwether Pharma and the recently announced partnership with Actavis. The Australian market for generic medicines is significant and growing strongly. The company continues to experience strong revenue growth and has a portfolio of products that collectively account for a significant proportion of total generic sales in the Australian market.

Commercial terms remain confidential but include a cash investment and the provision of in-kind value providing Generic Health with access to 16 dossiers of generic products with a total market size exceeding A\$800 million with 14 of these approved by the necessary regulatory bodies.

BTC is a major shareholder in Generic Health and has Board representation.

Press release from Generic Health follows.

Further information can be found at [www.biotechcapital.com.au](http://www.biotechcapital.com.au), [www.generichealth.com.au](http://www.generichealth.com.au) and [www.lupinword.com](http://www.lupinword.com).

### **About BioTech Capital Ltd**

BioTech Capital Ltd ("BTC") is one of Australia's largest life-science focused private equity funds. With approximately \$6 million in investment funds still available, the company is well placed to continue to develop a diversified portfolio of high quality Australian life-science investments.

BTC currently has investments in a diverse group of Australian life-science companies including Alchemia, Biocomm, Continnence Control Systems, Generic Health, Neurodiscovery, Pacific Knowledge Systems, Phylogica, Sensear, Starpharma, Stem Cell Sciences and XRT. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income.

BTC is listed on the Australian Stock Exchange (Code: BTC) and is managed externally by Titan BioVentures Management ([www.titanbioventures.com](http://www.titanbioventures.com)). Additional information can be found at [www.biotechcapital.com.au](http://www.biotechcapital.com.au)



## **GENERIC HEALTH SECURES INVESTMENT FROM LUPIN LIMITED**

**Melbourne, Australia 25 August 2008;**

Generic Health Pty Ltd, an Australian owned and operated generic pharmaceutical company headquartered in Melbourne, Australia, has today announced that it has secured a strategic investment from Lupin Limited which is among the top five pharmaceutical companies in India and a significant global supplier.

Since its formation in 2004, Generic Health has been providing quality generic medicines to the Australian market via highly competitive and sustainable partnerships. Generic Health is well advanced in its plans to become a significant player in the Australian generics pharmaceutical industry. This announcement follows on from Generic Health's recently announced partnership with **Actavis** in June this year and the acquisition of **Bellwether Pharma** in 2007.

Lupin's investment complements existing supply arrangements for a number of products with a total market size exceeding A\$800m. "Lupin's equity investment will result in no change in the day-to-day operations of Generic Health" and our customers will benefit significantly from greater resources and access to competitive products." said Gavin Upiter Managing Director, Generic Health.

Commenting on the development Mr. Vinod Dhawan, Regional President, Lupin Limited said. "Our investment in Generic Health reflects our commitment to expand our business in Australia. We have built a significant business in this market leveraging our existing alliances with leading local generic companies which we will continue to nurture and grow."

"The new investment arrangement with Lupin will support our longer term market share ambitions and contribute to our long term growth strategy, market supply and range of pharmaceutical products in the Australian market." said Generic Health Managing Director, Gavin Upiter.

-----  
**About Generic Health ([www.generichealth.com.au](http://www.generichealth.com.au))**

Generic Health Pty Ltd is a privately held, fast growing Australian owned and operated pharmaceutical company, marketing, selling and distributing a range of generic pharmaceutical prescription and OTC medications. Generic Health's strategic focus has been on delivering low cost, high quality products linked to simplified and transparent transactions. Generic Health was founded in 2004 by Mr Gavin Upiter.

**For more information, please contact:**

Mr Gavin Upiter

Managing Director, Generic Health Pty Ltd

**P:** +61 3 9809 7900 or +61 407 726 822

**E:** [gavin.upiter@generichealth.com.au](mailto:gavin.upiter@generichealth.com.au)

**About Lupin ([www.lupinworld.com](http://www.lupinworld.com))**

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the advanced and emerging markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporin's and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top five pharmaceutical companies of India. For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively.